These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10853628)

  • 1. Non-ergot dopamine agonist-induced sleep attacks.
    Ryan M; Slevin JT; Wells A
    Pharmacotherapy; 2000 Jun; 20(6):724-6. PubMed ID: 10853628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing dopamine agonists in Parkinson's disease.
    Bonuccelli U
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S13-9. PubMed ID: 15180133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["Sleep attacks" in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?].
    Möller JC; Stiasny K; Cassel W; Peter JH; Krüger HP; Oertel WH
    Nervenarzt; 2000 Aug; 71(8):670-6. PubMed ID: 10996919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep attacks in patients receiving dopamine-receptor agonists.
    Plowman BK; Boggie DT; Morreale AP; Schaefer MG; Delattre ML; Chan H
    Am J Health Syst Pharm; 2005 Mar; 62(5):537-40. PubMed ID: 15745920
    [No Abstract]   [Full Text] [Related]  

  • 5. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.
    Frucht S; Rogers JD; Greene PE; Gordon MF; Fahn S
    Neurology; 1999 Jun; 52(9):1908-10. PubMed ID: 10371546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep attacks in patients taking dopamine agonists: review.
    Homann CN; Wenzel K; Suppan K; Ivanic G; Kriechbaum N; Crevenna R; Ott E
    BMJ; 2002 Jun; 324(7352):1483-7. PubMed ID: 12077032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.
    Kujawa K; Leurgans S; Raman R; Blasucci L; Goetz CG
    Arch Neurol; 2000 Oct; 57(10):1461-3. PubMed ID: 11030798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
    Etminan M; Gill S; Samii A
    Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of pramipexole and its clinical utility in Parkinson's disease.
    Biglan KM; Holloway RG
    Expert Opin Pharmacother; 2002 Feb; 3(2):197-210. PubMed ID: 11829733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of dopamine agonists.
    Lam YW
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):17S-25S. PubMed ID: 10641988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
    Hobson DE; Lang AE; Martin WR; Razmy A; Rivest J; Fleming J
    JAMA; 2002 Jan 23-30; 287(4):455-63. PubMed ID: 11798367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 17. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alopecia induced by dopamine agonists.
    Tabamo RE; Di Rocco A
    Neurology; 2002 Mar; 58(5):829-30. PubMed ID: 11889256
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.
    Driver-Dunckley E; Samanta J; Stacy M
    Neurology; 2003 Aug; 61(3):422-3. PubMed ID: 12913220
    [No Abstract]   [Full Text] [Related]  

  • 20. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.